From GlobeNewswire: 2025-06-03 09:40:00

The global Gabapentin market was valued at USD 2.33 billion in 2023, projected to reach USD 3.55 billion by 2032 with a 4.75% CAGR. Factors driving growth include increased cases of epilepsy, neuropathic pain, and off-label use for fibromyalgia and anxiety. The U.S. market is expected to grow to USD 0.94 billion by 2032 at a 4.78% CAGR, driven by high chronic pain prevalence and rising epilepsy rates. Hospital pharmacies dominated distribution in 2023, accounting for 48.59% of market revenue. North America led the market with 36.62% global market share in 2023, while Asia Pacific is expected to see growth due to rising epilepsy and diabetes-related neuropathy cases. Major players in the market include Teva Pharmaceutical, Pfizer Inc., and Sun Pharmaceutical Industries Ltd. Recent advancements include Teva Pharmaceuticals’ extended-release gabapentin and Pfizer Inc.’s research on chemotherapy-induced neuropathy control using gabapentin.



Read more at GlobeNewswire: Gabapentin Market Size to Hit USD 3.55 Billion by 2032,